Takeda Pharmaceutical Co. $TAK Stock: Ethic Inc. Boosts Position

Ethic Inc. grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 19.5% during the third quarter, Holdings Channel reports. The firm owned 436,514 shares of the company’s stock after acquiring an additional 71,261 shares during the period. Ethic Inc.’s holdings in Takeda Pharmaceutical were worth $7,940,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently modified their holdings of TAK. Renaissance Technologies LLC raised its stake in shares of Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after purchasing an additional 370,800 shares during the last quarter. Quantinno Capital Management LP boosted its position in Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after buying an additional 219,999 shares during the last quarter. Royal Bank of Canada increased its holdings in Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 614,851 shares of the company’s stock worth $11,386,000 after buying an additional 60,725 shares during the period. Bleakley Financial Group LLC increased its holdings in Takeda Pharmaceutical by 19.0% in the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after buying an additional 68,844 shares during the period. Finally, QRG Capital Management Inc. increased its holdings in Takeda Pharmaceutical by 1.4% in the 2nd quarter. QRG Capital Management Inc. now owns 372,752 shares of the company’s stock worth $5,975,000 after buying an additional 5,064 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $21.02 on Monday. The firm has a market capitalization of $67.35 billion, a P/E ratio of 27.65 and a beta of -0.02. The stock has a 50-day simple moving average of $19.12 and a two-hundred day simple moving average of $17.67. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.60 and a current ratio of 1.15. Takeda Pharmaceutical Co. has a fifty-two week low of $13.56 and a fifty-two week high of $21.73.

Wall Street Analysts Forecast Growth

Several brokerages have commented on TAK. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Weiss Ratings raised shares of Takeda Pharmaceutical from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, November 3rd. Finally, Zacks Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy”.

Insider Buying and Selling

In other Takeda Pharmaceutical news, insider Giles Platford sold 55,617 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $20.90, for a total value of $1,162,395.30. Following the completion of the transaction, the insider directly owned 270,253 shares of the company’s stock, valued at approximately $5,648,287.70. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Deidre Greenway sold 12,980 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $18.11, for a total value of $235,067.80. Following the completion of the transaction, the insider directly owned 40,049 shares of the company’s stock, valued at $725,287.39. The trade was a 24.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 238,974 shares of company stock valued at $4,549,461 in the last three months. 0.04% of the stock is currently owned by insiders.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company is a Japan-based global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Founded in Osaka in 1781 as a medicine wholesaler, it has grown into an international pharmaceutical business headquartered in Tokyo.

The company focuses on gastroenterology and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments for conditions such as inflammatory bowel disease and hereditary angioedema, along with medicines and vaccines across its other therapeutic areas.

Takeda serves patients and healthcare providers in Japan and markets around the world.